Artificial intelligence–enabled liquid biopsy in cancer: a systematic review and meta- analysis of diagnostic performance and biological implications - Takeaways - MDSpire

Artificial intelligence–enabled liquid biopsy in cancer: a systematic review and meta- analysis of diagnostic performance and biological implications

  • By

  • Luisana Sisca

  • Mariam Grazia Polito

  • Emy Sisca

  • Michele Iuliani

  • Alessio Cortellini

  • Bruno Vincenzi

  • Giuseppe Tonini

  • Francesco Pantano

  • June 17, 2026

  • 0 min

Share

  • 1

    AI-enhanced liquid biopsy achieved a pooled AUROC of 0.924, indicating strong diagnostic performance across multiple cancer types.

  • 2

    AI models demonstrated a consistent absolute AUROC improvement of 0.025 over conventional methods in head-to-head comparisons.

  • 3

    Liquid biopsy offers a minimally invasive alternative to tissue biopsy, allowing real-time monitoring of tumor evolution.

  • 4

    The integration of AI can help overcome limitations of liquid biopsy, such as low analyte abundance and biological noise.

  • 5

    Future clinical application of AI-enhanced liquid biopsy requires prospectively validated models tailored to specific diagnostic needs.

Original Source(s)

Artificial intelligence–enabled liquid biopsy in cancer: a systematic review and meta- analysis of diagnostic performance and biological implications

  • by Luisana Sisca, Mariam Grazia Polito, Emy Sisca, Michele Iuliani, Alessio Cortellini, Bruno Vincenzi, Giuseppe Tonini, Francesco Pantano

  • June 17, 2026

Related Content

2026 AACR Bladder Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from AACR 2026.

  • June 17, 2026

  • 1 min
Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma

Access to Specialty Cancer Care and Plan Disenrollment Among Medicare Beneficiaries